AU2014256546B2 - Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level - Google Patents
Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level Download PDFInfo
- Publication number
- AU2014256546B2 AU2014256546B2 AU2014256546A AU2014256546A AU2014256546B2 AU 2014256546 B2 AU2014256546 B2 AU 2014256546B2 AU 2014256546 A AU2014256546 A AU 2014256546A AU 2014256546 A AU2014256546 A AU 2014256546A AU 2014256546 B2 AU2014256546 B2 AU 2014256546B2
- Authority
- AU
- Australia
- Prior art keywords
- general formula
- tamoxifen
- triphenylphosphonium
- alkyl
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 title claims abstract description 163
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims abstract description 96
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims abstract description 96
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 230000001613 neoplastic effect Effects 0.000 title claims abstract description 17
- 229960001603 tamoxifen Drugs 0.000 claims abstract description 101
- -1 aliphatic triphenylphosphonium derivatives Chemical class 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 13
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 81
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 51
- 208000026310 Breast neoplasm Diseases 0.000 claims description 50
- 206010006187 Breast cancer Diseases 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 39
- 230000002438 mitochondrial effect Effects 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 239000012300 argon atmosphere Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 11
- 239000000262 estrogen Substances 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 claims description 10
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000005880 cancer cell killing Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 88
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 210000003470 mitochondria Anatomy 0.000 description 37
- 201000011510 cancer Diseases 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 229960000575 trastuzumab Drugs 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 150000001299 aldehydes Chemical class 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 230000006907 apoptotic process Effects 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 9
- 210000001700 mitochondrial membrane Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical group C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 5
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 4
- 229960004891 lapatinib Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000006540 mitochondrial respiration Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- RETKRHPDLMXYMK-UHFFFAOYSA-M 9-[tert-butyl(dimethyl)silyl]oxynonyl-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCO[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 RETKRHPDLMXYMK-UHFFFAOYSA-M 0.000 description 3
- NYGWNUVHCNGDPR-UHFFFAOYSA-M 9-hydroxynonyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCO)C1=CC=CC=C1 NYGWNUVHCNGDPR-UHFFFAOYSA-M 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000006950 reactive oxygen species formation Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108010078640 respiratory complex II Proteins 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HAUSOYOTQFEFKE-UHFFFAOYSA-L triphenyl(9-triphenylphosphaniumylnonyl)phosphanium;dibromide Chemical compound [Br-].[Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CCCCCCCCC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HAUSOYOTQFEFKE-UHFFFAOYSA-L 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- WGAXVZXBFBHLMC-UHFFFAOYSA-N 1,9-dibromononane Chemical compound BrCCCCCCCCCBr WGAXVZXBFBHLMC-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000015845 Oestrogen-related receptors Human genes 0.000 description 1
- 108050004056 Oestrogen-related receptors Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 230000006546 aerobic glycolytic metabolism Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000010655 carbometalation reaction Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108091008916 nuclear estrogen receptors subtypes Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5449—Polyphosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
- C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/14—Styryl dyes
- C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/008—Dyes containing a substituent, which contains a silicium atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ304553B6 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZPV2014-66 | 2014-01-29 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014256546A1 AU2014256546A1 (en) | 2015-11-12 |
| AU2014256546B2 true AU2014256546B2 (en) | 2017-03-30 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014256546A Ceased AU2014256546B2 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2989110B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6375091B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101764991B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105452265B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014256546B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2909994C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120821T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2989110T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029881B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2699099T3 (cg-RX-API-DMAC7.html) |
| GE (1) | GEP20186868B (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20181872T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE042239T2 (cg-RX-API-DMAC7.html) |
| MD (1) | MD4626C1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ713589A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2989110T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2989110T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2989110T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA116469C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014173374A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10548318B2 (en) * | 2015-07-03 | 2020-02-04 | Bayer Cropscience Aktiengesellschaft | N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action |
| BR112018000088B1 (pt) * | 2015-07-03 | 2022-07-12 | Bayer Cropscience Aktiengesellschaft | Derivados de n-(1,3,4-oxadiazol-2-il)aril carboxamida com ação herbicida, seu uso, composição herbicida, e método para controle de plantas indesejadas |
| EP3368011A4 (en) * | 2016-07-12 | 2019-07-10 | Accutar Biotechnology Inc. | NOVEL CONNECTIONS AND USE THEREOF |
| AU2017312499B2 (en) | 2016-08-19 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| CA3063717C (en) | 2017-05-19 | 2021-08-24 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| CA3079952A1 (en) | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration |
| SG11202004729QA (en) | 2017-11-24 | 2020-06-29 | Lunella Biotech Inc | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| CA3085375A1 (en) | 2017-12-20 | 2019-06-27 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mdivi-1 derivatives |
| EP3955935A4 (en) * | 2019-04-16 | 2023-01-18 | Lunella Biotech, Inc. | ALKYL-TPP COMPOUNDS FOR MITOCHONDRIAL TARGETING AND ANTI-CANCER TREATMENTS |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551434B1 (en) * | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| JP4648319B2 (ja) * | 2003-08-22 | 2011-03-09 | アンティポディーン ファーマシューティカルズ インコーポレイティド | ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体 |
| CN1997403A (zh) * | 2004-07-13 | 2007-07-11 | 奥里迪斯生物医学研究及开发有限责任公司 | 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途 |
| USRE47300E1 (en) * | 2008-03-14 | 2019-03-19 | Cancure Limited | Mitochondrially delivered anti-cancer compounds |
| US20100297262A1 (en) * | 2009-04-17 | 2010-11-25 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja active Active
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en active Active
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Non-Patent Citations (2)
| Title |
|---|
| MOREIRA, P.I. et al. "Tamoxifen and Estradiol Interact with the Flavin Mononucleotide Site of Complex I Leading to Mitochondrial Failure" The Journal of Biological Chemistry (2006) Vol.281 No.15 pages 10143 to 10152 * |
| SMITH, R.A.J. et al. "Delivery of bioactive molecules to mitochondria in vivo" Proceedings of the National Academy of Sciences (2003) Vol.100 No.9 pages 5407 to 5412 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016522179A (ja) | 2016-07-28 |
| NZ713589A (en) | 2017-12-22 |
| CN105452265B (zh) | 2017-05-10 |
| HK1216317A1 (zh) | 2016-11-04 |
| EA201591918A1 (ru) | 2016-02-29 |
| US20160075726A1 (en) | 2016-03-17 |
| PT2989110T (pt) | 2018-11-15 |
| UA116469C2 (uk) | 2018-03-26 |
| US9896466B2 (en) | 2018-02-20 |
| SI2989110T1 (sl) | 2019-01-31 |
| PL2989110T3 (pl) | 2019-03-29 |
| MD4626C1 (ro) | 2019-11-30 |
| CN105452265A (zh) | 2016-03-30 |
| EA029881B1 (ru) | 2018-05-31 |
| CY1120821T1 (el) | 2019-12-11 |
| GEP20186868B (en) | 2018-06-25 |
| MD20150117A2 (ro) | 2016-08-31 |
| JP6375091B2 (ja) | 2018-08-15 |
| MD4626B1 (ro) | 2019-04-30 |
| WO2014173374A1 (en) | 2014-10-30 |
| KR20150144756A (ko) | 2015-12-28 |
| HUE042239T2 (hu) | 2019-06-28 |
| ES2699099T3 (es) | 2019-02-07 |
| CA2909994A1 (en) | 2014-10-30 |
| DK2989110T3 (en) | 2018-12-03 |
| EP2989110B1 (en) | 2018-08-08 |
| AU2014256546A1 (en) | 2015-11-12 |
| CA2909994C (en) | 2018-06-26 |
| KR101764991B1 (ko) | 2017-08-10 |
| EP2989110A1 (en) | 2016-03-02 |
| HRP20181872T1 (hr) | 2019-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014256546B2 (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level | |
| Burmaoglu et al. | Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents | |
| Xu et al. | Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents | |
| Jaouen et al. | Ferrocifen type anti cancer drugs | |
| JP2016522179A5 (cg-RX-API-DMAC7.html) | ||
| Du et al. | Design, synthesis and biological evaluation of iridium (III) complexes as potential antitumor agents | |
| Sun et al. | Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR | |
| Yang et al. | A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway | |
| Shan et al. | First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway | |
| Luo et al. | Discovery of 3-(2-aminobenzo [d] thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition | |
| Barman et al. | A potent estrogen receptor and microtubule specific purine-benzothiazole-based fluorescent molecular probe induces apoptotic death of breast cancer cells | |
| CN104592091B (zh) | 一种含吲哚乙酸核心结构的化合物及其应用 | |
| CZ304553B6 (cs) | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 | |
| Diamantis et al. | Development of a novel apigenin prodrug programmed for alkaline-phosphatase instructed self-inhibition to combat cancer | |
| JP6423349B2 (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| Usman et al. | A novel biocompatible formate bridged 1D-Cu (ii) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells | |
| CZ201466A3 (cs) | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 | |
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| EP3487490A1 (en) | Compounds for targeting cancer stem cells | |
| Liu et al. | A novel cinnamic acid derivative for hepatocellular carcinoma therapy by degrading METTL16 protein | |
| Li et al. | Microbe-based fluorescent sensor composite for drug delivery and hepatocellular carcinoma suppression | |
| Chen et al. | Structure-guided discovery of nitrobenzo-2-oxa-1, 3-diazole (NBD) scaffold-based PFKFB4 inhibitors for cancer therapy | |
| PL235564B1 (pl) | Zastosowanie białek z grupy ALKBH w sposobie diagnozowania chorób nowotworowych in vitro oraz pochodne antrachinonu do zastosowania do leczenia lub zapobiegania rozwojowi nowotworu nosogardła i/lub elementów układu pokarmowego | |
| Generation et al. | Molecular Sciences | |
| WO2010120337A1 (en) | Mitochondrial inhibitors to treat human disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: SMART BRAIN S.R.O. Free format text: FORMER NAME(S): NEUZIL, JIRI; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; SMART BRAIN S.R.O.; KKCG SE Owner name: BIOTECHNOLOGICKY USTAV AV CR, V.V.I. Free format text: FORMER NAME(S): NEUZIL, JIRI; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; SMART BRAIN S.R.O.; KKCG SE Owner name: KKCG AG Free format text: FORMER NAME(S): NEUZIL, JIRI; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; SMART BRAIN S.R.O.; KKCG SE Owner name: NEUZIL, J. Free format text: FORMER NAME(S): NEUZIL, JIRI; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; SMART BRAIN S.R.O.; KKCG SE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NEUZIL, JIRI Free format text: FORMER OWNER(S): NEUZIL, JIRI; SMART BRAIN S.R.O.; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; KKCG AG Owner name: SPRINGTIDE VENTURES S.R.O Free format text: FORMER OWNER(S): NEUZIL, JIRI; SMART BRAIN S.R.O.; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; KKCG AG Owner name: BIOTECHNOLOGICKY USTAV AV CR, V.V.I. Free format text: FORMER OWNER(S): NEUZIL, JIRI; SMART BRAIN S.R.O.; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; KKCG AG Owner name: SMART BRAIN S.R.O. Free format text: FORMER OWNER(S): NEUZIL, JIRI; SMART BRAIN S.R.O.; BIOTECHNOLOGICKY USTAV AV CR, V.V.I.; KKCG AG |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |